Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer
Inavolisib plus palbociclib and ET demonstrated a manageable safety profile, lack of DDIs, and promising preliminary antitumor activity.
Authors
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Sravanthi Cheeti (ORCID: https://orcid.org/0000-0003-2933-6328)
- Ian E. Krop (ORCID: https://orcid.org/0000-0002-6380-5944)
- Jennifer L. Schutzman (ORCID: https://orcid.org/0009-0007-3697-5300)
- Andréa Varga (ORCID: https://orcid.org/0000-0002-1314-384X)
- Philippe Lucien Bedard (ORCID: https://orcid.org/0000-0002-6771-2999)
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Valentina Gambardella (ORCID: https://orcid.org/0000-0001-6081-8830)
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Stephanie Hilz (ORCID: https://orcid.org/0000-0002-6995-6719)
- Kevin Kalinsky (ORCID: https://orcid.org/0000-0002-3113-7902)
- Melissa Accordino (ORCID: https://orcid.org/0000-0002-4156-7279)
- Noopur Shankar (ORCID: https://orcid.org/0009-0005-5698-6782)
- Nicholas C. Turner (ORCID: https://orcid.org/0000-0001-8937-0873)
- Peter Schmid (ORCID: https://orcid.org/0000-0001-9817-5228)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Ubong Peters (ORCID: https://orcid.org/0000-0002-2491-9519)
- Stephanie Royer‐Joo (ORCID: https://orcid.org/0000-0003-4205-9927)
- Cristina Saura (ORCID: https://orcid.org/0000-0001-8296-5065)
- Dejan Juric (ORCID: https://orcid.org/0000-0003-2983-7704)
- Katherine E. Hutchinson (ORCID: https://orcid.org/0000-0002-4660-3523)
- Andrés Cervantes (ORCID: https://orcid.org/0000-0003-3806-3691)
- Yanling Jin (ORCID: https://orcid.org/0009-0004-6546-5201)
Institutions
- University Health Network (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Institute of Cancer Research (GB)
- Emory University (US)
- Université de Bordeaux (FR)
- Universitat de València (ES)
- Queen Mary University of London (GB)
- University of Toronto (CA)
- Cornell University (US)
- Columbia University Irving Medical Center (US)
- Instituto de Salud Carlos III (ES)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- Yale Cancer Center (US)
- Massachusetts General Hospital (US)
- Roche (Canada) (CA)
- Sarah Cannon (US)
- Royal Marsden Hospital (GB)
- Vall d'Hebron Hospital Universitari (ES)
- INCLIVA Health Research Institute (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1200/jco.24.00110
- Citations
- 30
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Pfizer
- F. Hoffmann-La Roche
- Memorial Sloan-Kettering Cancer Center